Mass Tort Watch, June 2026: Roundup's $7.25 Billion Settlement, Record Talc Verdicts, and What New Yorkers Should Know

Last reviewed: June 2026

Key Takeaways

• Bayer announced a $7.25 billion settlement structure for Roundup claims on February 17, 2026. A Missouri judge granted preliminary approval on March 4. Payments would be tiered by exposure type, age at diagnosis, and cancer severity — averaging roughly $165,000 for the strongest occupational cases and far less for most others.
• More than 60,000 Roundup suits remain active, and the settlement is being fought hard. Objectors took the unusual step of removing the settlement case to federal court on May 22, 2026; the opt-out deadline passed June 4, and the final approval hearing is set for July 9 — after the Supreme Court is expected to rule on FIFRA preemption in Monsanto v. Durnell.
• Talc litigation produced the largest single-plaintiff award in its history: a $1.56 billion Baltimore mesothelioma verdict in December 2025, alongside a $65.5 million Minnesota verdict and a $40 million Los Angeles ovarian-cancer award. Every one is on appeal — headline numbers are not collected numbers.
• A mass tort is not a class action. In a mass tort you keep an individual claim with individual proof and an individual payout; that distinction controls everything from your deadline to your settlement check.
• Mass tort TV ads are mostly lead generation, not lawyering. Many are run by marketing companies that sell your name to firms you have never heard of. There are concrete red flags — and a concrete picture of what a real case evaluation looks like.
• New Yorkers have New York problems a national firm will not handle: CPLR §214-c discovery-rule deadlines, Medicare and Medicaid liens, estate and wrongful-death issues, and fee-sharing disclosures. Local counsel still matters even when the litigation is national.

This is the first edition of Mass Tort Watch, a recurring series tracking the national mass tort dockets that actually matter to New Yorkers. The reason for the series is simple: mass tort coverage is dominated by television-advertising mills and settlement-amount clickbait, and almost none of it tells you what a New York claimant actually needs to know — what the deadlines are, how the money really flows, and when a national sign-up form is the wrong move.

I represent injured plaintiffs and insurance defendants in New York courts every week. This series is the sober practitioner read: verified numbers, primary sources, and the parts the TV ads leave out.

Mass Tort vs. Class Action: The Distinction That Controls Everything

The single most common misconception I hear from callers who responded to a TV ad is “I joined the class action.” Usually they did no such thing — and the difference is not academic. It determines whether you have your own case, your own deadline, your own proof burden, and your own check.

One wrinkle worth flagging: Bayer structured its 2026 Roundup deal as a class settlement in Missouri state court — a class-action vehicle wrapped around what has always been mass tort litigation. That hybrid structure is precisely what the objectors are attacking, as covered next.

Roundup in 2026: The $7.25 Billion Settlement and the Fight Over It

On February 17, 2026, Bayer announced a proposed nationwide settlement worth up to $7.25 billion intended to resolve current and future claims that its glyphosate-based Roundup weedkiller causes non-Hodgkin lymphoma (NHL). The deal was filed in the Circuit Court of the City of St. Louis, Missouri, and a judge granted preliminary approval on March 4, 2026.

The scale of what came before explains why Bayer wants a global exit: the company has already paid out more than $10 billion in earlier Roundup settlements and verdicts since 2020, and more than 60,000 suits remain active — most in state courts. Under the proposed structure, Bayer would fund annual payments over a period of up to 21 years, with individual payouts tiered by exposure history, age at diagnosis, and disease severity. Reported averages run from roughly $165,000 for the strongest cases (occupational exposure, diagnosis before 60, aggressive NHL) down to $20,000 or less for many residential-use claims, and around $10,000 for those diagnosed at 78 or older. Treat those figures as the deal’s own projections, not a promise about any individual case.

The objectors’ unusual removal gambit

This settlement is not gliding to approval. Critics — including lawyers for nearly 20,000 existing plaintiffs — say the deal was negotiated without broad input, pays its architects handsomely (a reported $675 million in fees to the negotiating attorneys), and delivers comparatively little to cancer victims. A May 2026 filing went further, arguing the settlement structure violates due process by using a class vehicle to cap the rights of future claimants.

Then came the procedural curveball. On May 22, 2026, attorney Ashley Keller filed a notice of removal on behalf of ten objectors, yanking the settlement case from Missouri state court to federal court — on the theory that the objectors are functionally the defendants of the settlement proceeding, since Monsanto and the settling plaintiffs are aligned on the same side. Monsanto moved to remand, calling the removal “baseless and untimely”. Removal is a defendant’s tool; settlement objectors invoking it is genuinely rare, and how the federal court treats it will tell you a lot about whether the July approval schedule holds.

Meanwhile, the opt-out deadline passed on June 4, 2026, and the final approval hearing is set for July 9, 2026 — deliberately scheduled after the Supreme Court is expected to decide Monsanto v. Durnell, argued April 27, 2026. Durnell asks whether the federal pesticide statute (FIFRA) preempts state failure-to-warn claims because EPA never required a cancer warning on Roundup’s label. If Monsanto wins broadly, tens of thousands of pending failure-to-warn claims could be wiped out — which is exactly the leverage dynamic hovering over everyone’s settle-or-fight decision this month.

Who qualifies — and the New York exposure scenarios I actually see

Eligibility under the proposed settlement turns on a Roundup exposure history plus an NHL diagnosis, with exposure predating the settlement announcement. Beyond that, every qualification question is individual, and anyone promising you a number before reviewing your records is selling something.

That said, the New York exposure profiles that most plausibly support a claim are not hypothetical. They are people I recognize from this practice:

• Landscaping and grounds crews. Long Island’s lawn-care economy ran on glyphosate for decades — commercial applicators, golf-course staff, cemetery and school-grounds workers with seasonal, repeated exposure.
• Municipal workers. Parks department, highway department, and right-of-way maintenance employees who sprayed herbicide as part of the job, often with minimal protective equipment in the earlier years.
• Long Island agriculture. Suffolk County’s East End remains one of New York’s most productive farm regions — nurseries, sod farms, vineyards, and row-crop operations where occupational glyphosate exposure was routine.
• Heavy residential users. Decades of weekend spraying matters less than occupational exposure under the settlement tiers, but sustained home and garden use is still a recognized category.

Two hedges, stated plainly. First, a diagnosis plus exposure does not equal a payable claim — causation in NHL cases is contested, individual medical history matters, and the settlement’s own tiers discount older diagnoses and lighter exposure. Second, deadlines are personal. New York’s CPLR §214-c generally allows three years from the date a latent-exposure injury was or should have been discovered — but how that interacts with the settlement’s registration machinery and the Durnell decision is exactly the kind of question to put to a lawyer now, not after the July 9 hearing. Our personal injury practice screens these inquiries without charge.

Talc in 2026: Record Verdicts, Real Asterisks

If Roundup is the settlement story of the season, talc is the verdict story. Johnson & Johnson — which pulled talc-based baby powder from North American shelves in 2020 and worldwide in 2023 — absorbed three significant plaintiff wins in a matter of weeks:

• Baltimore — $1.56 billion (December 22, 2025). A Baltimore City jury awarded the largest single-plaintiff talc verdict ever to Cherie Craft, diagnosed with peritoneal mesothelioma after decades of baby-powder use: roughly $59.8 million compensatory plus $1 billion in punitive damages against J&J and $500 million against a subsidiary. J&J’s legal chief called the verdict “egregious and patently unconstitutional” and is appealing.
• Minnesota — $65.5 million (December 2025). A Ramsey County jury awarded $65.5 million to Anna Jean Houghton Carley, a 37-year-old mother of three who developed mesothelioma in the lining of her lungs after childhood baby-powder exposure. J&J is appealing.
• Los Angeles — $40 million (December 2025). A jury awarded $40 million in compensatory damages to two women with ovarian cancer — notable as the first plaintiffs’ verdict in a talc–ovarian cancer trial since 2021, and the first of roughly ten such trials expected through mid-2026. J&J, which notes it has won 16 of 17 ovarian-cancer talc trials, is appealing.

Now the asterisk, because this series exists to give you the asterisks: on March 13, 2026, a Los Angeles judge threw out a $950 million punitive award from a different October 2025 talc verdict, finding the plaintiffs had not clearly and convincingly proven malice — leaving only the $16 million compensatory portion. A $966 million headline became a $16 million judgment in one ruling. Expect motion practice and appeals to compress the December verdicts too. Headline verdicts move settlement leverage; they are not checks.

For New Yorkers: talc claims remain individually filed (there is no open “sign-up” settlement comparable to Roundup’s), eligibility generally requires a mesothelioma or qualifying ovarian-cancer diagnosis plus a documented talc-use history, and the same CPLR §214-c discovery-rule analysis applies. Every case differs — diagnosis type, exposure proof, and venue dramatically change value.

How Mass Tort Settlements Actually Pay (the Part the Ads Skip)

Television ads imply a simple trade: sign up, receive “significant compensation.” Here is the sober version, in general terms (every settlement program differs):

1. Points matrices, not jury numbers. Global settlements typically assign each claimant points based on objective criteria — diagnosis type and severity, age at diagnosis, exposure duration and intensity, smoking or other confounding history. Your dollar figure is your points multiplied by a fund-driven dollar value. The Roundup proposal’s tiering ($165,000 average for strong occupational cases down to roughly $10,000–$20,000 for weaker categories) is a textbook example.
2. Liens come off the top. If Medicare, Medicaid, the VA, or a private health plan paid for your cancer treatment, they generally have reimbursement rights against your recovery — federal law requires Medicare conditional payments to be resolved, and New York Medicaid asserts its own claims. Lien negotiation can materially change your net, and mishandling it can stall payment for a year or more.
3. Fees and costs are deducted. Contingency fees plus litigation costs and claims-administration assessments all reduce the gross figure.
4. Payment is slow and sometimes staged. Funds that pay out over years (Roundup proposes up to 21), appellate reversals (see the $950 million example above), and appeals-driven escrows all mean the timeline is measured in years, not weeks. Those long timelines are also why mass tort claimants get pitched pre-settlement funding advances — if you take one, the payoff comes out of your net, and after a 2025 New York appellate ruling your funding paperwork may itself be discoverable.
5. Deficient documentation is the most common reason claims pay zero. Programs deny or discount claims that cannot produce pathology reports, prescription or purchase histories, or employment records establishing exposure. This is where real lawyering — assembling the proof — earns its fee.

If you want to understand how individual New York injury cases are valued outside the mass tort context, our settlement calculator walks through the methodology New York lawyers and adjusters actually use.

Social Media MDL: A Brief Word

We cover this docket separately, but the June development belongs in any mass tort roundup: after a Los Angeles jury returned the first personal-injury verdict against Meta and YouTube — $6 million — on March 25, 2026, the litigation moved to its next phase, with the first federal bellwether trial (a school-district claim) opening in the Northern District of California in mid-June. Our full trial-watch analysis is here: Social Media MDL: the first bellwether trial, June 2026, and our explainer for New York families is here: Social media addiction lawsuits in New York.

Red Flags When You Respond to a Mass-Tort TV Ad

Here is the consumer-protection section, and the reason this series will never read like the ads. I watch those spots with a professional wince, because I take the calls that follow them — people who e-signed something six months ago and cannot tell me the name of their own lawyer. A large share of mass tort advertising is not placed by law firms at all. It is placed by lead-generation companies that collect your information and sell it. New York’s litigation-advertising economy is enormous: trial-lawyer ad spending in this state hit $179 million in 2025, and a meaningful slice of it is mill marketing. (That ad glut is part of what fueled this year’s New York tort reform fight.)

None of this means national mass tort firms are illegitimate — the best of them are excellent. It means the intake funnel between you and a competent lawyer is full of intermediaries with no duty to you. We have written before about how this plays out in specific products litigation — see our analyses of the Sig Sauer P320 litigation and COVID-19 vaccine injury claims, both areas where aggressive marketing outran the actual legal merits for many claimants.

When a New York Firm Refers Into National Litigation — and Why Local Counsel Still Matters

A candid disclosure about how this works, because almost nobody explains it: when a New York firm evaluates a Roundup or talc inquiry and concludes the claim belongs in a national settlement program or an out-of-state coordinated proceeding, the usual move is a referral or co-counsel arrangement with a firm that handles that docket at volume. New York’s Rules of Professional Conduct permit fee division between firms only with the client’s informed consent and full disclosure — if nobody told you a second firm is involved, that itself is a red flag.

So why involve a New York lawyer at all? Because the national firm handles the national questions, and everything else lands on you:

• Your deadline is a New York deadline. CPLR §214-c discovery-rule analysis, tolling questions, and wrongful-death timing under New York law are not the national firm’s daily work.
• Your liens are New York liens. New York Medicaid recovery, hospital liens, and private-plan reimbursement claims need local handling.
• Death changes everything. If the injured person has died, a New York estate must be raised in Surrogate’s Court and wrongful-death distribution rules apply before any settlement can be approved and paid.
• Settlements involving minors or wrongful death require New York court approval — a local procedural step that stalls many national settlements for months when nobody owns it.
• Someone local should read the retainer and the points award. An independent New York lawyer reviewing a settlement allocation costs you little and catches a lot.

This firm sits on both sides of that pipeline — we evaluate, we refer when referral serves the client, we stay in as local counsel when New York issues need an owner, and we litigate New York product cases directly. Our results reflect that mix.

Talk to a New York Lawyer Before You Sign Anything

If you or a family member has a non-Hodgkin lymphoma diagnosis with a Roundup exposure history, a mesothelioma or ovarian-cancer diagnosis with a talc history, or you have already signed something from a TV ad and want a second set of eyes on it, call (516) 750-0595 or contact us online for a free consultation. We will tell you plainly whether you have a claim worth pursuing, where it belongs, and what it should cost you — and if the honest answer is “you don’t qualify,” you will get that answer too.

For attorneys: we accept co-counsel, local-counsel, per-diem, and appellate engagements on New York product liability and mass tort–adjacent matters — including Surrogate’s Court proceedings, infant-compromise and wrongful-death settlement approvals, and lien resolution supporting national settlements. Attorney inquiries answered same day.

Frequently Asked Questions

How much will the Roundup settlement pay per person in 2026?

Under Bayer’s proposed $7.25 billion structure, reported payment projections are tiered: the strongest cases — occupational exposure, diagnosis before age 60, aggressive non-Hodgkin lymphoma — average around $165,000, while many residential-use claims project at roughly $20,000 and diagnoses at 78 or older around $10,000. These are program projections, not guarantees; liens, fees, and documentation quality all change the net, and the settlement still requires final court approval (hearing set for July 9, 2026).

Can I still file a Roundup lawsuit in New York in 2026?

Possibly — but the analysis is urgent and individual. The settlement’s opt-out deadline passed on June 4, 2026, the Supreme Court’s Monsanto v. Durnell preemption decision is expected by the end of June, and New York’s CPLR §214-c generally allows three years from discovery of a latent-exposure injury. Where your specific dates fall determines everything. Get a New York-specific deadline analysis before assuming you are in or out.

What is the difference between a mass tort and a class action?

In a mass tort (Roundup, talc), thousands of people file individual lawsuits against the same defendant; each plaintiff proves individual injury and receives an individually valued recovery. In a class action, one representative case binds an entire class — typically for uniform, smaller harms — and members receive formula-based payments unless they opt out. Roundup’s 2026 deal blurs the line by using a class-settlement vehicle for mass tort claims, which is a core objection now being litigated.

Is the $1.56 billion talc verdict final?

No. Johnson & Johnson is appealing the December 2025 Baltimore verdict and has called it unconstitutional. Large punitive awards are routinely reduced or vacated after trial — in March 2026 a Los Angeles judge struck a $950 million punitive award from a different talc verdict entirely, leaving $16 million. Verdicts shape settlement leverage, but the amount a plaintiff ultimately collects is usually far lower than the headline.

Are the mass tort lawsuit ads on TV legitimate?

Some are placed by real law firms; many are placed by lead-generation companies that sell your information to firms you have never heard of. Warning signs include no named attorney, instant “qualification” without medical records, implied dollar amounts, and pressure to e-sign a retainer immediately. A legitimate evaluation involves a named lawyer reviewing your pathology and exposure records before anyone discusses value — and full written disclosure if a second firm will share the work and the fee.

Do I need a New York lawyer if my Roundup or talc case is part of national litigation?

It usually helps, and sometimes it is essential. New York controls your statute of limitations (CPLR §214-c), your Medicaid and hospital liens, court approval of any settlement involving a minor or a wrongful-death claim, and Surrogate’s Court proceedings if the injured person has died. National counsel handles the national litigation; a local lawyer makes sure the New York pieces don’t stall or shrink your recovery.

This article reports on pending litigation and proposed settlements as of June 2026. Settlement terms, deadlines, and appellate outcomes change quickly; nothing here is legal advice about any individual claim, and every case differs. For advice about your situation, contact the Law Office of Jason Tenenbaum, P.C. at (516) 750-0595.